WuXi NextCODE Announces Executive Leadership Transition

Rob Brainin, Chief Executive Officer at WuXi NextCODE

Genomic data platform, WuXi  NextCODE announced yesterday that Rob Brainin, Executive Vice President and Chief Operating Officer, has been appointed as the company’s new Chief Executive Officer.  

Mr. Brainin, who will lead the next phase of the company’s growth, succeeds Hannes Smárason, who will work as a senior advisor for the company as he pursues other entrepreneurial activities. 

“The board and I would like to thank Hannes for the many contributions he made to WuXi NextCODE. Our mission is to create a truly global CGO and genomic data platform with powerful solutions to enable anyone, and any company to benefit from the genome, and we look forward to Rob’s leadership in our next phase of growth,” said Dr. Ge Li, Chairman of WuXi NextCODE, and Chairman of WuXi AppTec Group.

 

Google Partnership With WuXi NextCODE to Bring Sequencing to the Cloud

 

 
Hannes Smárason

Hannes Smárason, Senior Advisor, WuXi NextCODE

“It has been a pleasure to grow WuXi NextCODE to a global leader in genomics. The decision to step down was made easier by our strong management team and Rob’s proven track record of achievement in some of the most successful major enterprises in our space. I look forward to supporting Rob and the executive team in transitioning the Chief Executive role,” Mr. Smárason commented.

“This is an exciting time at WuXi NextCODE as we execute our vision to enable anyone to use the genome to improve health and wellness worldwide,” said Mr. Brainin. “Our global genomic data platform is moving from a position of leadership to transforming the future of healthcare. I’m honoured to lead WuXi NextCODE alongside extraordinary colleagues and partners.”

Mr. Brainin has been overseeing the company’s global operations and commercial efforts since 2017. Prior to that, he had rich experience at Illumina, Thermo Fisher, Life Technologies, and Invitrogen, commercializing technologies and leading businesses that serve life sciences research customers and customers utilizing genomics in applied markets. He holds a degree in economics from Emory University and a J.D. degree from Harvard Law School

More on these topics